Healthcare Industry News: schizophrenia
News Release - September 25, 2008
Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic DisordersSAN DIEGO, Sept. 25 (HSMN NewsFeed) -- OrexigenŽ Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced that Dr. Dennis Kim has joined the Company as Senior Vice President and Head of Obesity and Metabolic Disorders. Dr. Kim will be leading the clinical development activities for the Company's obesity franchise.
"I am thrilled to be joining the team at Orexigen at such an exciting time," said Dr. Kim. "I'm looking forward to working with the leadership team at Orexigen to bring to market our two obesity treatment candidates, ContraveŽ and Empatic(TM)."
Dr. Kim brings more than seven years of pharmaceutical experience to Orexigen. He joins the Company from EnteroMedics, Inc., where he served as Chief Medical Officer and Vice President of Medical Affairs. Prior to that, Dr. Kim worked at Amylin Pharmaceuticals where he was Executive Director, Corporate Strategy. There, he played a significant role in the Company's alliance with Eli Lilly, including the development and launch of ByettaŽ.
Dr. Kim holds an M.D. from the Chicago Medical School. He completed his internal medicine residency at Rush Presbyterian St. Luke's Medical Center and an endocrinology fellowship at the University of California, San Diego (USCD) School of Medicine. Dr. Kim also holds a Master of Business Administration degree from UCSD's Rady School of Business.
"Orexigen focuses on expertise, experience and excellence in addressing senior management positions," said Gary Tollefson, M.D., Ph.D., Orexigen President and CEO. "Dr. Kim will be a key addition to Orexigen, bringing not only a deep expertise in obesity and metabolic disorders to the Company, but also a strong background in strategy, medical affairs and management."
The Senior Vice President and Head of Obesity and Metabolic Disorders is a new position at Orexigen. Dr. Kim will report to Eduardo Dunayevich, M.D., Chief Medical Officer.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, including obesity. The Company's lead combination product candidates targeted for obesity are ContraveŽ, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.
Source: Orexigen Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.